BREAST CANCER STEM-LIKE CELLS: CLINICAL IMPLICATIONS AND THERAPEUTIC STRATEGIES

OANA MIHAELA TUDORAN¹,², OVIDIU BALACESCU¹, IOANA BERINDAN-NEAGOE¹²

¹Department of Functional Genomics and Experimental Pathology, I. Chiricuta Oncology Institute, Cluj-Napoca, Romania
²Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania

Abstract

Breast cancer is the most frequently diagnosed cancer in women, being also the leading cause of cancer death among female population, including in Romania. Resistance to therapy represents a major problem for cancer treatment. Current cancer treatments are both expensive and induce serious side effects; therefore ineffective therapies are both traumatic and pricey. Characterizing predictive markers that can identify high-risk patients could contribute to dedicated/personalized therapy to improve the life quality and expectancy of cancer patients. Moreover, there are some markers that govern specific tumor molecular features that can be targeted with specific therapies for those patients who are most likely to benefit. The identification of stem cells in both normal and malignant breast tissue have lead to the hypothesis that breast tumors arise from breast cancer stem-like cells (CSCs), and that these cells influence tumor’s response to therapy. CSCs have similar self-renewal properties to normal stem cells, however the balance between the signaling pathways is altered towards tumor formation. In this review, we discuss the molecular aspects of breast CSCs and the controversies regarding their use in the diagnosis and treatment decision of breast cancer patients.

Keywords: cancer stem-like cells, breast cancer, signaling pathways, targeting strategies

Introduction

Malignant neoplasms are the second cause of death, after heart diseases, and it is estimated to rank first beginning with 2010. Worldwide, 12.7 million people were diagnosed with some type of cancer in 2008, 56% of the cases resulting in death [1]. Breast cancer is the most frequently diagnosed cancer in women, being also the leading cause of cancer death among female population, including in Romania according European Cancer Observatory. If diagnosed at early stages, the overall five-year relative survival among US women is 98%, but drops to 84% and 23% when the disease has spread to regional lymph nodes or distant organs [2]. Early detection through mammography and improved treatments has increased the survival of these patients in westernized countries [3], however some breast cancer patients fail to respond to conventional treatments, leading to tumor recurrence. This can be caused by baseline resistance due to intrinsic factors, or acquired during therapy.

Breast cancer prognosis is dependent on the number of lymph nodes involved, tumor size, histological grade, and hormone receptor status. Even so, even after an accurate classification, tumors can respond to treatment in a surprising way, and the prognosis can vary. In order to
explain these observations, other factors such as Her2 gene amplification, EGFR family members, cell cycle fraction analysis, p53 mutations, presence of circulating tumor cells and lymphovascular invasion are being investigated for prognostic and predictive value. Therefore, therapy selection requires the consideration of not only the clinical status of the patient but also the molecular characteristics of the tumor. Current systemic treatments of breast cancer include cytotoxic, hormonal, and immunotherapeutic agents, medications that are administered in adjuvant, neoadjuvant, and metastatic settings. Molecular analysis classifies breast tumors into four major subtypes: luminal A and B, HER2-overexpressing and basal-like tumors, treatment regimens being dependent on the patient breast tumor molecular subtype. With the advancement of new chemotherapeutics, hormone and biological agents and the integration of systemic therapy with surgery and radiation therapy, treatment plan decision is proving to become more complicated.

**The CSCs concept**

Despite early detection and molecular classification of breast tumors have improved breast cancer patients outcome, approximately 30% of early-stage breast cancer cases relapse. In general, cancer reappears at distant sites, thereby strengthening the hypothesis that breast cancer is a systemic disease. Currently, the research is focused on finding and characterizing specific markers that can identify high-risk patients and have the potential to be developed as a targeting strategy for future therapies.

Recent molecular studies have emphasized a series of molecular particularities that have been involved in therapy response and disease relapse [4-6], however tumor heterogeneity complicates the study and treatment of breast cancer. Several cell populations exist within a single tumor; moreover there are differences within the same cell populations [7]. Two models have been proposed to describe tumor heterogeneity (Figure 1): in the non-hierarchical model (Figure 1A), cells undergo a clonal evolution, all cells having equal chances to acquire genetic lesions and develop a malignant phenotype, while the hierarchical model (Figure 1B) proposes the cancer stem-like cells (CSCs) concept, in which a subset of cells act as multipotent progenitors that drive tumor growth. Recent isolation of subpopulations of tumor cells that have stem cells related cell behavior supports the CSC hypothesis.

Advances in stem-cell technology have made possible the identification of stem cells in normal and malignant breast tissue. “Primitive” stem-like tumor-initiating cells have been previously identified within breast tumors [8], therefore suggesting that CSCs are responsible for breast tumors heterogeneity [9]. More and more reports provide evidence that breast tumors arise from breast cancer stem-like cells (CSCs) [10], and that these cells influence tumor response to therapy [4-6]. CSCs are slowly proliferating cells, quiescent in G0 phase for long periods of time; hence they may escape conventional treatments that mainly target actively proliferating cells. CSCs have similar self-renewal properties to normal stem cells, however the balance between the signaling pathways is altered towards tumor formation [11]. CSCs are not necessarily transformed normal stem cells, but rather a mix between the two models (Figure 1C) [12] could explain the genetic instability and plasticity of tumor cells. CSCs may arise from restricted progenitors or differentiated cells by acquiring stem cell-like properties and further undergo clonal selection to generate different subtypes of breast cancers (Triple negative, Her2-gene amplified, luminal).

**CSCs identification and functional analysis**

CSCs can be identified based on functional activity (self-renewal, serial tumor propagation) and phenotypic markers (CD44+/CD24−, aldehyde dehydrogenase-1 (ALDH) activity) [13]. CD44 has been positively associated with stem cell-like characteristics and CD24 expression is related to differentiated epithelial features [14].

Immunohistochemistry staining is the only standardized accepted diagnostic tool and this method has been previously used to detect CSCs in breast cancer patients [15]. However, immunohistochemistry analysis cannot assess CSCs functionality, therefore this detection method needs to be correlated with functional assay of CSCs activity.

The ‘gold standard’ methods for assessing CSC activity experimentally are in vivo tumor formation and serial transplantation assays. Studying CSCs in isolated systems, such as cell cultures, has its limitations, it has been suggested that breast CSCs require a particular niche in which to grow for maintenance [16]. There is an active crosstalk between tumors and the microenvironment, microenvironmental effects can influence the induction of the epithelial-to-mesenchymal transition (EMT) of breast cancer cells [11], a process that is associated with CSCs enrichment of tumors [17].

In vivo transplantation methods are technically challenging, lengthy, expensive, with ethical implications and impractical in clinical trial settings. Alternative in vitro methods such as mammosphere assays and identification of cell surface markers such as CD44+/CD24− have been previously utilized in pre-clinical studies and in pre-surgical window trials.

**CSCs signaling pathways and targeting strategies**

Understanding the molecular mechanisms that govern tumor resistance is imperative for individualized medicine as well as for future treatment developments. Several studies have showed that breast CSCs are associated with resistance to standard radiation and chemotherapy [18,19], moreover these cells are enriched following treatment driving tumor recurrence and metastases [20].

Several mechanisms have been described to be responsible for CSCs resistance phenotype the most characterized being increased drug efflux transporters, increased DNA repair machinery and increased antiapoptotic
proteins expression [21]. Potential ways to target these mechanisms have been described, which include inducing cell differentiation to inhibit the self-renewal properties, promote apoptosis, targeting resistance mechanisms or the CSC niche.

Several groups, (including ours), have used transcriptomic analysis to investigate and predict the tumor response to treatment in order to identify patients with high risk of treatment failures. These studies generated a tremendous amount of data; hundreds of genes have been found to be over or down regulated after treatment, moreover, the data among groups is often inconsistent. According to the theory that treatment resistance is given by the CSCs presence within the tumor mass, these studies need to be reassessed to take into consideration the significance of CSCs populations. CSCs abundance within tumors can be associated and varies with ER, PR, Her2 expression and molecular subtype (Table I). Studies have showed that not all tumors present CSCs [15,22-29], but their presence is associated with poorer outcome [27]. To our knowledge, there are very few gene expression studies that assessed the gene signature of CSCs within the tumors [20,30], but these studies compared CSCs signatures with those of tumor cells, thus important information regarding the CSCs plasticity to tumor cells and vice versa could have been lost. CSCs signaling pathways described so far are common both to normal stem cells and cancer biology and it has not brought us closer to clarify whether CSCs arise from normal stem or cancer cells. Moreover, there are no defined drugs that specifically target CSCs in the clinic.

Aberrant Notch, Hedgehog, Wnt, EGFR and Nf-kB pathways have been described to maintain malignant stem cell activity [31]. In a recent study [32], we have identified stem cells pluripotency signaling pathways to be regulated as response to treatment. We have identified several canonical pathways to be involved in treatment response, among which some that are known to be involved in stem cells pluripotency. When we measured this activity by mammosphere assay, we observed that the treated cells formed smaller mammospheres, but the number of CSCs was little affected if at all when compared to untreated cells, which sustains CSCs enrichment and tumor re-bulking theory.
Several similarities have been observed between CSCs and epithelial mesenchymal transition (EMT) state. Both normal and malignant breast stem cells can adopt either EMT or MET (mesenchymal to epithelial transition) states, which are inter-convertible. The preferences for one or the other states at a given point is regulated by complex signals that originate in the microenvironment, these in turn, activate signaling cascades within the CSC population. Each of the two states have distinct characteristics: CSCs with mesenchymal morphological features that express CD24-/CD44+, EpCAM-/CD49f+ are considered in the EMT state, these cells being largely quiescent and present increased invasiveness. CSCs with dynamic self-renewal activity and expression of ALDH and EpCAM+/CD49f+ are in MET state, while cells that express both CD24-/CD44+ and ALDH may be in transition between these states. The existence of multiple states further complicates the study of CSCs and the development of effective therapeutic strategies. Targeting Notch pathway with γ-secretase inhibitors (DAPT, MK-0752, RO4929097) has been showed to significantly reduce CSCs activity both in vitro and in vivo settings being currently tested in phase I/II clinical trials [33, 34]. Moreover, Notch inhibitors are tested in combination with Hedgehog inhibitors GDC-0049, as these two pathways interact with each other to maintain self-renewal [35]. Transgenic mice lacking specific ABC transporters showed increased drug sensitivity, however, the use of ABC drug transporters like BCRP and ABCG2 increases the risk of neurotoxic effects [36].

Due to the length of time and funds it takes to study a new drug and get it approved for clinical use, researchers are lately revisiting old drugs that are currently used in other pathologies but are known to target pathways altered in CSCs. For example, Metformin (used for type 2 diabetes treatment) combined with conventional therapy has been showed to further reduce tumor growth in triple negative breast cancer by specifically targeting CSCs [37]. Also retinoids and rexinoids, strong inducers of differentiation, are currently used in some types of leukemia and has been showed to induce breast CSCs differentiation [38]. PARP inhibitors are being tested to target the CSCs DNA repair machinery [39], so far results are not clear. So far, compounds that target CSCs have been identified mostly throughout technologies employing automated drug screening. Salinomycin, a recently described CSCs specific drug has been found after screening around 16000 compounds [40]. This method is expensive, laborious and time consuming. Moreover, some of the identified drugs are facing with the challenge of selective CSCs targeting in comparison with normal stem cells as these agents are targeting pathways that are vital in development (Notch, Wnt, Hedgehog), thus limiting their clinical applicability. Therefore, a robust analysis of the basic science must precede clinical trials in order to find drugs that could specifically target CSCs.

Overall, standard therapies in combination with CSC-targeted therapies may potentially provide a more effective treatment strategy by de-bulking the tumor mass and preventing recurrence [31].

**Conclusions**

There is a common belief that targeting CSCs provides a promising approach for cancer prevention and treatment [41-43], therefore the CSCs model became the foundation of preventive and therapeutic strategies in cancer. It has been showed that CSCs have important implications for early detection, prevention, and treatment of breast cancer [44-46], but the clinical and prognostic impact of these markers in breast cancer remains a controversial

---

**Table I. Distribution of CD44+/CD24− phenotype according to breast cancer expression of ER, PR, Her2 receptors.**

| Subtype | Luminal A | Her2− | TNBC |
|---------|-----------|-------|-------|
| ER | PR | Her2 | |
| Luminal A | 16.6 | 17.6 | 44.8 | [28] |
| Luminal B | 7 | 3.1 | 10.9 | [24] |
| TNBC | 8 | 23 | [29] |
| Luminal A | 5.6 | 0.36 | 0.61 | [25] |
| Luminal B | 23.8 | 19.2 | - | [26] |
| TNBC | 36.8 | 7.8 | 26.7 | 60 | [27] |

*n=number of patients

---

| n* | ER | PR | Her2 | Subtype | Luminal A | Her2− | TNBC |
|----|----|----|------|---------|-----------|-------|-------|
| 132 | 12.1 | 13.6 | 12.1 | 13.6 | 16.6 | 28.1 | 44.8 | [28] |
| 121 | 4.4 | 7.2 | 1.6 | 10.5 | 7 | 4.4 | - | - | - | - | [22] |
| 57 | 21.1 | 78.9 | 28.1 | 71.9 | - | - | - | - | - | - | [23] |
| 156 | 13.1 | 24.1 | 17.2 | 18.7 | 27.9 | 7.4 | 1.6 | 21.1 | 3.1 | 10.9 | [24] |
| 54 | 17 | 8 | 19 | 2 | - | - | 8 | 23 | [29] |
| 818 | 1 | 4.27 | 1.5 | 4.27 | 5.6 | 0.4 | 4.76 | 0.36 | 0.61 | [25] |
| 156 | 13.1 | 24.1 | 17.2 | 18.7 | 27.9 | 7.4 | 1.6 | 21.1 | 3.1 | 10.9 | [24] |
| 38 | 36.8 | 7.8 | 26.7 | 60 | [27] |
issue, demanding additional efforts to elucidate the role of CSCs in breast cancer management. Alterations in the stem-cell self-renewal pathways may be responsible for both hereditary and sporadic breast cancers, making them attractive targets for the development of cancer preventive strategies. Furthermore, because CSCs are highly resistant to radiation and chemotherapy, the development of future anti-cancer therapies may require the active targeting of this cell population. Therefore, two main questions remain: are CSCs ready for the clinic, but also, is the clinic is ready for CSCs?

Acknowledgements
This work was financed by the POSCCE 709/2010 grant with the title: “Clinical and economical impact of proteom and transcriptom molecular profiling in neoadjuvant therapy of triple negative breast cancer (BREASTIMPACT)”, and published under the frame of European Social Fund, Human Resources Development Operational Programme 2007–2013, project no. POSDRU/159/1.5/S/138776.

References
1. Society AC. World Cancer Facts & Figures 2nd Edition2011.
2. Altekruse SF. Cancer Statistics Review 1975-2007.
3. Althuis MD, Dozier JM, Anderson WF, Devesa SS, Brinton LA. Global trends in breast cancer incidence and mortality 1973-1997. Int J Epidemiol. 2005;34(2):405-412.
4. Osborne CK, Schif R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62:233-247.
5. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009;9(9):631-643.
6. Moitra K, Lou H, Dean M. Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development. Clin Pharmacol Ther. 2011;89(4):491-502.
7. Merlo LM, Pepper JW, Reid BJ, Maley CC. Cancer as an evolutionary and ecological process. Nat Rev Cancer. 2006;6(12):924-935.
8. Giatromanolaki A, Sivridis E, Fiska A, Koukourakis MI. The CD44+/CD24- phenotype relates to ‘triple-negative’ state and unfavorable prognosis in breast cancer patients. Med Oncol. 2011;28(3):745-752.
9. Campbell LL, Poljak K. Breast tumor heterogeneity: cancer stem cells or clonal evolution?. Cell Cycle. 2007;6(19):2332-2338.
10. Liu S, Wicha MS. Targeting breast cancer stem cells. J Clin Oncol. 2010;28(25):4006-4012.
11. Charafe-Jauffret E, Monville F, Ginestier C, Donut G, Birnbaum D, Wicha MS. Cancer stem cells in breast: current opinion and future challenges. Pathobiology. 2008;75(2):75-84.
12. Greaves M. Cancer stem cells: back to Darwin?. Semin Cancer Biol. 2010;20(2):65-70.
13. Fillmore CM, Kupershaw C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res. 2008;10(2):R25.
14. Park SY, Lee HE, Li H, Shipitsin M, Gelman R, Poljak K. Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res. 2010;16(3):876-887.
15. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1(5):555-567.
16. Croker AK, Allan AL. Cancer stem cells: implications for the progression and treatment of metastatic disease. J Cell Mol Med. 2008;12(2):374-390.
17. Santisteban M, Reiman JM, Asiedu MK, Behrens MD, Nassar A, Kalli KR, et al. Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res. 2009;69(7):2887-2895.
18. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008;100(9):672-679.
19. Debebr BG, Xu W, Mok H, Li L, Robertson F, Ueno NT, et al. Differential radiosensitizing effect of valproic acid in differentiation versus self-renewal promoting culture conditions. Int J Radiat Oncol Biol Phys. 2010;76(3):889-895.
20. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A. 2009;106(33):13820-13825.
21. Chuthapisith S, Eremin J, El-Shemeys M, Eremin O. Breast cancer chemoresistance: emerging importance of cancer stem cells. Surg Oncol. 2010;19(1):27-32.
22. Zhong Y, Shen S, Zhou Y, Tao F, Guan J, Lin Y, et al. ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24-phenotype. Med Oncol. 2014;31(3):864.
23. Camerlingo R, Ferraro GA, De Francesco F, Romano M, Nicoletti G, Di Bonito M, et al. The role of CD44+/CD24-/low biomarker for screening, diagnosis and monitoring of breast cancer. Breast Cancer Res Treat. 2014;133(3):979-999.
24. Tanei T, Horimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, et al. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy. Clin Cancer Res. 2010;69(7):2887-2895.
25. Chekhun SV, Zadvorny TV, Tymovska YO, Anikusko MF, Novak OE, Polishchuk LZ. CD44+/CD24- markers of cancer stem cells in patients with breast cancer of different molecular subtypes. Exp Oncol. 2015;37(1):58-64.
ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity. Hum Pathol. 2013;44(3):402-411.
30. Liu R, Wang X, Chen GY, Dalerba P, Gurney A, Hoey T, et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med. 2007;356(3):217-226.
31. Aplette MP, Singh JK, Clarke RB. Stem cells in breast tumours: are they ready for the clinic?. Eur J Cancer. 2012;48(14):2104-2116.
32. Tudorana O, Soritana O, Balacescu L, Visan S, Barbos O, Cioceaneanu-Petric R, et al. Regulation of stem cells-related signaling pathways in response to doxorubicin treatment in Hs578T triple-negative breast cancer cells. Mol Cell Biochem. 2015;409(1-2):163-176.
33. Harrison H, Farnie G, Howell SJ, Rock RE, Stylianou S, Brennan KR, et al. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res. 2010;70(2):709-718.
34. Clinical Trials, MD Anderson Center, The University of Texas. Available from: [link to clinicaltrials.org]
35. Al-Hussaini H, Subramanyam D, Reeder M, Sridhar SS. Notch signaling pathway as a therapeutic target in breast cancer. Mol Cancer Ther. 2011;10(1):9-15.
36. An Y, Ongkeko WM. ABCG2: the key to chemoresistance in cancer stem cells?. Expert Opin Drug Metab Toxicol. 2009;5(12):1529-1542.
37. Hirsch HA, Iliopoulos D, Tsichlis PN, Stuhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009;69(19):7507-7511.
38. Ginestier C, Wicinski J, Cervera N, Monville F, Finetti P, Bertucci F, et al. Retinoid signaling regulates breast cancer stem cell differentiation. Cell Cycle. 2009;8(20):3297-3302.
39. O’Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med. 2011;364(3):205-214.
40. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009;138(4):645-659.
41. Song LL, Miele L. Cancer stem cells—an old idea that’s new again: implications for the diagnosis and treatment of breast cancer. Expert Opin Biol Ther. 2007;7(4):431-438.
42. Atkinson RL, Zhang M, Diagaradjane P, Peddibhotla S, Contreras A, Hilsenbeck SG, et al. Thermal enhancement with optically activated gold nanoshells sensitizes breast cancer stem cells to radiation therapy. Sci Transl Med. 2010;2(55):55ra79.
43. Korkaya H, Paulson A, Iovino F, Wicha MS. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene. 2008;27(47):6120-6130.
44. Bauerschmitz GJ, Ranki T, Kangasniemi L, Ribacka C, Eriksson M, Porten M, et al. Tissue-specific promoters active in CD44+/CD24- breast cancer cells. Cancer Res. 2008;68(14):5533-5539.
45. Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H. Prevalence of CD44+/CD24- cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res. 2005;11(3):1154-1159.
46. Snyder EL, Bailey D, Shipitsin M, Polyak K, Loda M. Identification of CD44v6(+)/CD24- breast carcinoma cells in primary human tumors by quantum dot-conjugated antibodies. Lab Invest. 2009;89(8):857-866.